NCT03481946View on ClinicalTrials.gov

A Study to Assess Pharmacokinetics and Pharmacodynamics Following Administration of BAY1093884 in Patients With Severe Hemophilia

PHASE1CompletedINTERVENTIONAL
Enrollment

6

Participants

Timeline

Start Date

May 10, 2018

Primary Completion Date

October 17, 2018

Study Completion Date

February 20, 2019

Conditions
Hemophilia A; Hemophilia B
Interventions
DRUG

BAY1093884

0.3 mg/kg given intravenously

DRUG

BAY1093884

1 mg/kg given intravenously

Trial Locations (1)

5262000

Chaim Sheba Medical Center, Ramat Gan

Sponsors

Lead Sponsor

Bayer
All Listed Sponsors
lead

Bayer

INDUSTRY

NCT03481946 - A Study to Assess Pharmacokinetics and Pharmacodynamics Following Administration of BAY1093884 in Patients With Severe Hemophilia | Biotech Hunter | Biotech Hunter